SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 57.11-3.7%10:57 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (233)5/31/2007 10:18:27 PM
From: david nordic  Read Replies (1) of 507
 
NKTR is paying off it debt with its cash bank.

NKTR expects Cimiza to be approved in 07. The FDA required additional studies for Crohn's disease which will not be completed until 08. This assumes the FDA is going to approve and require the studies to be completed ongoing. This is the first time this has been stated. UCB/Cimiza/NKTR.

NKTR has slow rolled future deals with partners waiting for new revenue to go it alone. In Q4 07 we will have a better view of Mircera, Cimiza, Exubera as well as phase I for Peg irinotecan, Phase II for Amikacin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News